Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Respiratory Disorders Treatment Market size was valued at USD 115.09 billion in 2024 and is expected to reach USD 251.57 billion by 2037, registering around 6.2% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of respiratory disorders treatment is assessed at USD 121.16 billion.
The primary factor for the growth of the market can be attributed to the increasing cases of respiratory disease worldwide. According to NCD alliance, 235 million people suffer from asthma worldwide. To cope with the large pool of patients companies are continuously working on innovating drugs to prevent or cure these diseases.
Respiratory Disorders Treatment Sector: Growth Drivers and Challenges
Growth Drivers
Increasing Cases of COVID-19 to Increase Demand for Respiratory Disease Drugs
Since the starting of 2020, we have witnessed an exponential growth in the number of cases of COVID-19 worldwide. In majority of the cases, patients show symptoms similar to that of respiratory diseases. Thereby, it has increased the demand for respiratory drugs. Increased demand coupled with the necessity of developing a vaccine with drive the respiratory disorders treatment market in upcoming few years.
Increasing Level of Air Pollution to Increase Cases for Respiratory Diseases
Most of the developing countries where rapid industrialization is happening, are witnessing an increase in the level of air pollution which is one of the primary risk factor for respiratory disorders treatment such as COPD and asthma. As per the Global Asthma report, 2018, more than 1 billion people are affected by pulmonary diseases. High level of pollution contributes to the increasing number of respiratory disease patients which can further lead to growth of respiratory disorders treatment market.
Challenges
Lack of Testing Infrastructure to Diagnose Respiratory Disorders Treatment to Hamper Growth
Most of the developing nations do not have good healthcare facilities and they lack in infrastructure and COVID-19 has clearly exposed this limitation. Treatment of any disease starts only when the disease is diagnosed but the lack of testing infrastructure makes it extremely difficult to diagnose diseases among countries with high population. This limitation may hamper the market growth for respiratory diseases.
Side Effects of Drugs to Hamper Growth
Most of the respiratory disease drugs have side effects and hence people hesitate in using these drugs. So there is a challenge in-front of drug manufacturing companies to innovate and prepare drug which have either no side effects or they have only a few non-severe side effects.
Respiratory Disorders Treatment Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
6.2% |
|
Base Year Market Size (2024) |
USD 115.09 billion |
|
Forecast Year Market Size (2037) |
USD 251.57 billion |
|
Regional Scope |
|
Respiratory Disorders Treatment Segmentation
The respiratory disorders treatment market is further segmented by disease type, drug class, route of administration, distribution channel and region. Disease type segment is further segmented into asthma, COPD, allergic rhinitis, pulmonary arterial hypertension, cystic fibrosis, and Others. The increasing pool of patients of Asthma coupled with its high prevalence is expected to drive the market. Moreover, the popularity of inhalational type of drugs is rising on the back of its fast action and quick relief comparing to the conventional dosage forms. Thereby, the growth in these segments is expected to drive the respiratory disorders treatment market as well.
The high prevalence of diseases such as Asthma and COPD has increased the demand for drugs in hospitals and diagnostic centres. Moreover, with the increasing popularity of online pharmacies the supply chain in the field of drug delivery is expected to improve tremendously. On the back of these factors the respiratory disorders treatment market is expected to grow notably over the forecast period.
Our in-depth analysis of the global market includes the following segments:
|
By Disease Type |
|
|
By Drug Type |
|
|
By Distribution Channel |
|
|
By Route of Administration |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportRespiratory Disorders Treatment Industry - Regional Synopsis
On the basis of regional analysis, the respiratory disorders treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region.
Currently, North America industry is anticipated to hold largest revenue share by 2037. The market is anticipated to grow significantly in Asia Pacific region during the forecast period owing to the increasing pool of the patients suffering from the disease and the rise in the air pollutants in the atmosphere.
Companies Dominating the Respiratory Disorders Treatment Landscape
- Mylan N.V.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Teva PharmaceuticalIndustries Ltd.
- Sunovion Pharmaceuticals Inc.
- Merck & Co., Inc.
- BoehringerIngelheim Pharmaceuticals, Inc.
- AstraZeneca Plc.
- GlaxoSmithKline Plc.
- Regeneron Pharmaceuticals, Inc.
- Grifols, S.A.
- Pfizer Inc.
In the News
- March 2020 - Mylan re-started production of generic hydroxychloroquine sulfate tablets (200mg) to meet increasing demand in the context of COVID-19. Company doanated 10 million tablets to US Department of Health and Human Services.
Author Credits: Radhika Pawar
- Report ID: 1121
- Published Date: Dec 23, 2024
- Report Format: PDF, PPT
